As treatment pathways in HR+/HER2− metastatic breast cancer become increasingly complex, sponsors face growing challenges in demonstrating therapeutic differentiation, identifying the right patient populations, navigating biomarker-driven development, and generating evidence that remains relevant across evolving treatment sequences.

This insight brief explores the key forces reshaping development strategy, including treatment sequencing, the expanding space between endocrine therapy and chemotherapy, biomarker fragmentation, resistance biology, and patient-centered value considerations. Learn how an adaptive development approach can help sponsors design more effective clinical programs, optimize patient selection, and position therapies for long-term clinical and commercial success.